Nearly 13 Percent of COVID-19 Hospitalized Patients Had Serious Neurologic Symptoms

Overwhelming evidence shows that infection with severe acute respiratory syndrome (SARS-CoV-2) causes dysfunction of multiple organ systems, including the nervous system. Neurologic symptoms are frequently reported even in patients with mild illness and for some, these neurologic symptoms may persist as part of long-haul COVID. To describe the prevalence, associated risk factors and outcomes of

Read More


Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain

Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells,

Read More


A NIH researchers study shows SARS-CoV-2 can persist in the body as long as 230 days

In what they describe as the most comprehensive analysis to date of the SARS-CoV-2 virus’s distribution and persistence in the body and brain, scientists at the U.S. National Institutes of Health said they found the pathogen is capable of replicating in human cells well beyond the respiratory tract. The results, released online Saturday in a

Read More


A Single-Cell analysis on blood antigen-presenting cells in severe COVID-19 shows induced Antiviral Immunity Defects

A number of antiviral immune defenses are compromised among people who develop severe COVID-19, a new single-cell RNA sequencing analysis has found. Some people infected with SARS-CoV-2 develop severe disease marked by acute respiratory failure and possibly sepsis and death. While studies have highlighted the possible role of systemic inflammatory responses in severe COVID-19, the

Read More


Towards Understanding AstraZeneca Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

A German researcher thinks he knows what has caused some people to develop blood clots after receiving coronavirus vaccines. University of Greifswald hematologist Andreas Greinacher believes the reaction is linked to EDTA, a preservative found in the AstraZeneca vaccine. The AstraZeneca vaccine contains more than 1,000 proteins that have been derived from human proteins —

Read More


33% can be the proportion of SARS-CoV-2 Infections That Are Asymptomatic for a Systematic Review

In the 14 studies with longitudinal data that reported information on the evolution of symptomatic status, nearly three quarters of persons who tested positive but had no symptoms at the time of testing remainedasymptomatic. Current data suggest that infected persons without symptoms—including both presymptomatic and asymptomatic persons—account for more than 40% of all SARS-CoV-2 transmission.

Read More


Oxford AstraZeneca vaccine could be approved in UK in the next weeks

he game-changing Oxford vaccination could get the go-ahead “just after Christmas”, a leading expert has said . John Bell, Regius Professor of Medicine at Oxford University, stressed the data behind the jab is looking “better than ever”. The Medicines and Healthcare products Regulatory Agency is examining the vaccine developed by Oxford University and pharmaceutical giant AstraZeneca. With an announcement from the MHRA eagerly anticipated, Prof Bell told

Read More


Wyss Institute researchers demonstrate machine-guided engineering of AAV capsids for gene therapy

High-throughput synthetic biology approach reveals hidden AAV features and could help fast-track future gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the wave of gene therapies that are in development in academic and biotechnology laboratories. However, natural AAVs do not specifically target diseased cells

Read More